Back to top

Image: Bigstock

The Zacks Analyst Blog Costco, T-Mobile US, Uber Technologies, SandRidge and Elite Pharmaceuticals

Read MoreHide Full Article

For Immediate Releases

Chicago, IL – November 26, 2024 – Zacks.com announces the list of stocks and featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include including Costco Wholesale Corp. (COST - Free Report) , T-Mobile US, Inc. (TMUS - Free Report) , Uber Technologies, Inc. (UBER - Free Report) , SandRidge Energy, Inc. (SD - Free Report) and Elite Pharmaceuticals, Inc. (ELTP - Free Report) .

Here are highlights from Tuesday’s Analyst Blog:

Top Stock Reports for Costco, T-Mobile US and Uber Technologies

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp., T-Mobile US, Inc. and Uber Technologies, Inc., as well as two micro-cap stocks, SandRidge Energy, Inc. and Elite Pharmaceuticals, Inc. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Costco’s shares have outperformed the Zacks Retail – Discount Stores industry over the last six months (+19.0% vs. +9.5%). The Zacks analyst believes that strategic investments, a customer-centric approach, merchandise initiatives and an emphasis on membership growth have been helping the company.

However, Costco faces stiff competition from BJ’s Wholesale Club and Sam’s Club, a division of Walmart Stores. These two rivals follow similar business models. Also, Costco's global presence exposes an inherent vulnerability to foreign currency fluctuations.

(You can read the full research report on Costco here >>>)

T-Mobile US’s shares have outperformed the Zacks Wireless National industry over the past year (+60.1% vs. +39.1%). The Zacks analyst believes that solid demand for postpaid services, solid growth in free cash flow and efficient capital management have aided the company.

Yet, the highly competitive and saturated nature of the U.S. wireless market could adversely affect its financial results. Declining prepaid ARPU remains a concern.

(You can read the full research report on T-Mobile US here >>>)

Shares of Uber have outperformed the Zacks Internet - Services industry over the past two years (+157.6% vs. +73.5%). Per the Zacks analyst, the company’s efforts to expand its delivery operations through successive acquisitions are encouraging. Continued recovery in Mobility operations is also aiding the company.

However, Uber continues to witness high costs and expenses owing to a rise in sales and marketing expenses and cost of revenues. Increased spending on driver incentives is also pushing up costs. High debt levels are bothersome as well.

(You can read the full research report on Uber here >>>)

Shares of SandRidge Energy have underperformed the Zacks Oil and Gas – Integrated – United States industry over the past year (-14.4% vs. -2.0%). Per the Zacks analyst, the company faces significant challenges due to declining natural gas prices and production volumes, which are pressuring revenues, cash flow and profitability. Its heavy reliance on the Mid-Continent region increases its exposure to regional risks.

Yet, recent strategic acquisitions targeted at enhancing the company’s stature are a part of SandRidge's ongoing efforts to optimize its asset base.

(You can read the full research report on SandRidge Energy here >>>)

Shares of Elite Pharma have outperformed the Zacks Medical – Drugs industry over the past year (+300.5% vs. +5.5%). Per the Zacks analyst, success of the Elite label products and expanding portfolio like high-value Abbreviated New Drug Applications for medications like Methotrexate and controlled substances have benefited. Its recent facility expansion enhances manufacturing capacity, supporting future product launches.

Yet, risks include customer concentration, pricing pressure from large buyers, intense competition, and regulatory challenges related to controlled substances. Supply chain vulnerabilities and potential overextension in product launches are other concerns.

(You can read the full research report on Elite Pharma here >>>)

Why Haven't You Looked at Zacks' Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.

Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                     

https://www.zacks.com                                                

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

Published in